Skip to content

for the planet

Servier Climate School

To effectively tackle environmental challenges, we must first understand them. That is why we launched the Servier Climate School in September 2023. The school offers accessible scientific and educational content (quizzes, videos and interactive lessons) to help employees better understand the environmental challenges and the impact they have on society and our operations. They offer an insight into the ways in which everyone can make a difference, both in their personal and professional lives.

Climate Fresk workshop creating awareness among employees regarding climate change

Climate focus

We have set targets to cut greenhouse gas emissions and developed a low-carbon strategy in energy, mobility, procurement of goods and services, as well as the distribution of our medicines. Our various departments strive to adapt and implement their own road maps to reflect these priorities.   

An ever-more ambitious commitment 

We aim to achieve: 


reduction in CO2 emissions across scopes 1 and 2 by 2030 compared to 2021-2022


reduction in CO2 emissions across scope 3 by 2030 compared to 2021-2022

Aligned with the objectives set out in the Paris Agreement, the new trajectory will be approved in 2024 by the SBTi, the international body setting the benchmark in terms of corporate action on climate.

Note : Scope 1 emissions occur directly from sources that are controlled or owned by the Group. Scope 2 emissions are associated with the purchase of electricity, steam, heat, or cooling. Scope 3 emissions include greenhouse gas emissions that are not directly related to producing the product but are caused instead by other stages of the medicine life cycle.  

Where we are with our carbon footprint 

– 11%

Reduction in scope 1 & 2 greenhous gas emissions in 2022-2023 as compared to the previous year

We take action in four key areas to achieve our objectives:

  • Decarbonizing our energy consumption by reducing the proportion of fossil energy used and increasing the proportion of renewable energy in our overall energy mix.

Year on year, we increase the proportion of renewable energy in our overall energy mix. Currently, half of our industrial facilities are equipped with photovoltaic panels that generate renewable electricity directly on site. Overall, five industrial facilities are fully self-sufficient in renewable electricity (Arklow in Ireland, Toledo and Madrid in Spain, and Jacarepagua and Pharlab in Brazil) as is our research center in Budapest, Hungary.  


Proportion of renewable electricity in our energy mix

-15 %

energy consumption in 2022-2023 as compared to the previous year

Solar panels on our production site at Toledo, Spain


of our industrial facilities are certified ISO 50001 or 14001 (Oril and Gidy in France, Arklow in Ireland, Anpharm in Poland, Toledo in Spain, Cairo in Egypt, Sophyno in Russia and Tianjin in China)


In 2022-2023, our energy consumption was reduced by 15%, as compared to the previous year.

  • Decarbonizing mobility, in particular by pursuing a strategy to transition our automotive fleet.

In our promotional subsidiaries in Belgium and Luxembourg, the new catalogue presents electric vehicles only. As we transition to an electric vehicle fleet, we are also installing charging points at our facilities, and conducting a feasibility study regarding the installation of solar panels in order to power these charging points.

  • Decarbonizing the procurement of goods and services by conducting operational actions to decarbonize the emissions related to the procurement of ingredients for brand-name medicines, category by category.

We require the suppliers involved with our brand-name medicine business to provide information regarding greenhouse gas emissions and systematically integrate climate data in assessments of companies responding to calls for tender.

  • Decarbonizing medicine transport, in particular by prioritizing the use of sea freight rather than air freight.

In 2022/2023, 57% of the Group’s intercontinental shipments went by sea, and 43% by air. Compared with last year, this represents a significant increase in the proportion of sea freight and a significant reduction in air freight.

Compensating our residual emissions

At the same time, we are pursuing a plan to offset a portion of our residual emissions through two greenhouse gas avoidance projects. By 2025, the aim is to reach 58,000 tons of CO2 equivalent per year. 

Positioning biodiversity and nature at the heart of our efforts 

In 2021, we once again underscored our commitment to protecting biodiversity and nature when we signed up to the Act4nature international initiative led by EpE (Entreprises pour l’Environnement). 

We have signed up to the ten commitments set out by the initiative, to which we have added our own:

  • measure and reduce the impact of our products and facilities on biodiversity 
  • reduce the impact of our facilities on biodiversity
  • raise awareness and develop skills among our employees around the challenges relating to biodiversity 
  • take part in projects to protect biodiersity 


Our water consumption fell by nearly 14% between 2021-2022 and 2022-2023, which represents a saving of 178,058 m3.​

With respect to our Act4Nature pledge: 

  • our calls for tender for raw materials include a biodiversity clause
  • we reduce the liquid effluent produced through our operations and will publish indicators to track this data in 2024
  • we will publish guidelines regarding the use of more environmentally friendly solvents in 2024​ 

Harnessing ecodesign to drive progress 

Throughout the entire medicine value chain (from the R&D phase through to the product end of life, and including raw material procurement, manufacturing, logistics, distribution and use), we see ecodesign as a key way to drive progress. We aim to reduce the impact of our operations on the environment while constantly maintaining efficacy and therapeutic safety standards.

The ecodesign program

  • We conduct life cycle analysis on our medicines to determine their environmental profile and identify which areas cause the greatest impact.​ 
  • Workshops bringing together operations representatives to identify and share best practice.​ 
  • We follow a road map that intends initially to bolster and disseminate our best practice.​ 
  • We share packaging recommendations with our suppliers.​

Our Green Score tool seeks to integrate the principles of green chemistry and ecodesign in synthetic substance activities for our medicines. It is currently being deployed and will enable us to assess the environmental impact of 100% of our new industrial chemical synthetic substances. 

In order to encourage more environmentally friendly choices, our industrial facilities are putting together packaging recommendations for our packaging design partners.